FDA Psychedelics Hearing Spotlights Infrastructure Gaps as Approval Nears — Multidisciplinary Association for Psychedelic Studies (MAPS)

Event summary

FDA held a Sept. 14 public hearing on psychedelic-assisted therapy, with MAPS attending and planning written testimony due by Oct. 5.
MAPS shared its Ibogaine Investigator's Brochure with federal health officials to update policy with current safety data.
FDA's recent guidance clarified trial design expectations but left unresolved issues like therapist training and insurance frameworks.
MAPS is coordinating with stakeholders to address systems readiness, therapist training, and patient access ahead of potential FDA approval.

The big picture

The FDA's hearing signals a maturation of the psychedelics field, with regulatory clarity now shifting focus to infrastructure readiness. While clinical promise is evident, systemic issues like therapist training and insurance access could delay real-world benefits for years. MAPS' coordination with stakeholders highlights the critical need for cross-sector collaboration to ensure equitable access once therapies are approved.

What we're watching

Regulatory Coherence: Whether FDA's guidance will sufficiently address systemic gaps in therapy infrastructure ahead of approval.
Access Barriers: How insurance frameworks and trained practitioner availability will impact patient access post-approval.
Stakeholder Collaboration: The pace at which researchers, clinicians, and advocates can align on licensing pathways and community health infrastructure.